News
Market Trends, Business Strategies, Competitive Intelligence, Clinical Trials, and Patent Trends Driving Growth from 2024 to 2029"Boston, July 10, 2025 (GLOBE NEWSWIRE) -- According to the latest ...
Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases. Promising results, but Phase ...
During a live event, Jeffrey V. Matous, MD, discussed bispecific antibody treatment efficacy and safety in advanced multiple ...
1d
Medpage Today on MSNEmerging Myasthenia Gravis TreatmentsIn recent years, the FDA has approved three complement inhibitors for gMG -- eculizumab (Soliris), ravulizumab (Ultomiris), ...
A team of researchers from the San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET, Milan), led by Nadia Coltella and ...
2d
Stockhead on MSNASX biotechs join global race for cell therapy breakthroughsSeveral ASX-listed biotechs are advancing cell therapies to capture a share of a global market projected to reach US$48 ...
While data is promising, many questions remain about topics such as timing and doses in the treatment of hematologic malignancies.
A team of physicians recently reported the successful treatment of refractory autoimmune neuropathies through the infusion of ...
A novel chimeric antigen receptor T-cell therapy may benefit patients with B-cell lymphomas who previously relapsed following ...
With immunotherapy increasingly making it out of the lab and into hospitals as a viable way to treat serious conditions like ...
US FDA eliminates REMS for autologous chimeric antigen receptor CAR T cell immunotherapies: Maryland Monday, June 30, 2025, 13:00 Hrs [IST] The US Food and Drug Administration (FD ...
5d
News-Medical.Net on MSNStudy unveils powerful strategy to rejuvenate effectiveness of CAR T cell therapy against glioblastomaA team of researchers from the San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET, Milan), led by Nadia Coltella and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results